"I completed my undergraduate studies in Biological Sciences at the University of
Navarra in 1988 and earned a PhD in Microbiology from the Center for Molecular
Biology (CSIC-UAM) at the Autonomous University of Madrid in 1992. I
subsequently spent three years conducting research in the laboratory of Professor
Pascale Cossart at the Pasteur Institute, focusing on the genetics of Listeria
monocytogenes actin-based motility. In 1997, I returned to Spain to join the Public
University of Navarra (UPNA) in Pamplona as a professor of Microbiology. The
following year, I was appointed Associate Professor and established my own
laboratory at the Center for Agrobiotechnology, where my research focused on the
genetics of bacterial biofilm formation. From 2010 to 2013, I served as Director of the
Center. In 2008, I became a Full Professor of Microbiology at UPNA, and between
2015 and 2022, I was Director of Navarrabiomed, a newly established biomedical
research institute in Pamplona. As a principal investigator, I have led nine consecutive
research projects funded by the Spanish Ministry of Economy, Industry, and
Competitiveness, as well as five grants from the European Union’s 6th, 7th, and
Horizon Europe Framework Programmes. I have supervised 20 doctoral students and
12 postdoctoral researchers, several of whom now lead their own research groups. My
laboratory is dedicated to studying the genetic mechanisms underlying biofilm
formation in pathogenic bacteria. Currently, our work focuses on the global function
of the two-component sensory network in Staphylococcus aureus, transcriptional gene
regulation through overlapping mRNAs of adjacent genes, and the development of
recombinant phages for therapeutic applications. Among our major scientific
contributions are: (i) the identification of a family of proteins, termed Bap, that
promote biofilm formation in various bacterial species through amyloid
conformations; (ii) the demonstration that the two-component sensory system is
dispensable for S. aureus growth under laboratory conditions; (iii) the discovery of a
transcriptional control mechanism based on overlapping mRNAs processed by RNase
III; and (iv) the identification of a novel bacterial gene organization, which we have
termed the non-contiguous operon. Throughout my career, I have been deeply
committed to translating scientific discoveries into tangible benefits for society. In
2011, I co-founded RECOMBINA S.L. (Pamplona), a biotechnology company
specialising in customised genetic engineering services and the development of
attenuated microorganisms for veterinary vaccine production."